Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

COLchicin und nicht magensaftresistent beschichtetes Aspirin in der Studie zu kardiovaskulären Ergebnissen bei Patienten mit Typ-2-Diabetes (COLCOT-T2D)

5. Oktober 2026 aktualisiert von: Montreal Heart Institute

COLchicin und nicht magensaftresistent beschichtetes Aspirin in der Studie zu kardiovaskulären Ergebnissen bei Patienten mit Typ-2-Diabetes (COLCOT-T2D)

To evaluate the efficacy and safety of colchicine and non-enteric coated aspirin, combined or alone, to improve cardiovascular outcomes in high-risk patients with type 2 diabetes.

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Geschätzt)

10000

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

55 Jahre bis 80 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Men and women aged 55 to 80 years

  2. Type 2 diabetes treated as per national guidelines

  3. No previous history of coronary artery disease-related clinical event

  4. And at least one of the following:

    1. Duration of diabetes of 5 years or more,
    2. HbA1c ≥ 8.0% or more in the last 2 years
    3. Active cigarette smoking,
    4. High hs-CRP (> 2.0 mg/L),
    5. High coronary calcium score (Agatston score >100),
    6. High TG-levels (≥1.7 mmol/L) despite lipid lowering therapy administered as per guidelines,
    7. High LDL-C levels (≥3.5 mmol/L) or high non-HDL-C levels (≥4.2 mmol/L) despite lipid lowering therapy administered as per guidelines
    8. High Apo-B (≥1.05 g/L)
    9. Reduced HDL-C (<1.05 mmol/L in men, <1.3 mmol/L in women),
    10. Lp(a) >50 mg/dL,
    11. Peripheral artery disease with stenosis ≥50% or prior revascularization,
    12. Cerebrovascular disease with stenosis ≥50% or prior revascularization,
    13. Diabetic retinopathy or diabetic neuropathy,
    14. Mild or moderate proteinuria (dipstick analysis) or micro-albuminuria
  5. Women of childbearing potential must have a negative urine pregnancy test at screening/randomization visit 1 and must agree to use an effective method of birth control throughout the study. Acceptable means of birth control include: oral contraceptives, implantable contraceptives, injectable contraceptives, transdermal contraceptives, intrauterine devices, male or female condoms with spermicide, abstinence, or a sterile sexual partner.

    Women are considered not of childbearing potential if they either:

    1. Have had a hysterectomy or tubal ligation prior to baseline visit or
    2. Are postmenopausal defined as no menses for 12 months or a FSH level (if available) in the menopausal range.
  6. Patients with the capacity to provide informed consent.

Exclusion Criteria:

  1. Any prior history of myocardial infarction, angina, coronary revascularization, coronary stenosis >30%, stroke, transient ischemic attack, or known heart failure

  2. Known chronic renal insufficiency defined as an estimated glomerular filtration rate (eGFR), using the MDRD equation, of < 35 mL/min/1.73m2

  3. History of cancer or lymphoproliferative disease within the last 3 years other than a successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix and/or low-grade prostate cancer

  4. Inflammatory bowel disease (Crohn's disease or ulcerative colitis) or chronic diarrhea

  5. Peptic ulcer diagnosed within the last 24 months or previous gastro-intestinal bleeding, except for mild hemorrhoidal bleeding more than 5 years ago which is permitted (patients meeting this exclusion criterion will not be randomized to receive aspirin or placebo but can be randomized to receive colchicine or placebo)

  6. Pre-existent progressive neuromuscular disease or known CPK level > 3 times the upper limit of normal as measured within the past 30 days and determined to be non-transient through repeat testing

  7. Any of the following known parameters as measured within the past 90 days, and determined to be non-transient through repeat testing:

    1. hemoglobin < 100 g/L
    2. 2. white blood cell count < 3.0 X 10⁹/L
    3. platelet count <110 X 10⁹/L
    4. ALT > 3 times the upper limit of normal (ULN)
    5. total bilirubin > 2 times ULN (unless due to Gilbert syndrome, which is allowed)
  8. History of cirrhosis, chronic active hepatitis or severe hepatic disease

  9. Female patient who is pregnant, or breast-feeding or is considering becoming pregnant during the study or for 6 months after the last dose of study medication

  10. History of clinically significant drug or alcohol abuse in the last year

  11. Patient is currently using or plans to begin chronic systemic steroid therapy (oral or intravenous) during the study (topical or inhaled steroids are allowed, as well as replacement corticosteroids for adrenal insufficiency)

  12. Current chronic treatment with aspirin or another antiplatelet agent (patients meeting this exclusion criterion will not be randomized to receive aspirin or placebo but can be randomized to receive colchicine or placebo)

  13. Chronic treatment with an anticoagulant agent (patients meeting this exclusion criterion will not be randomized to receive aspirin or placebo but can be randomized to receive colchicine or placebo)

  14. Current use of colchicine for other indications (mainly chronic indications consisting of Familial Mediterranean Fever or gout); there is no wash-out period required for patients who have been treated with colchicine and stopped treatment prior to enrolment

  15. History of an allergic reaction or significant sensitivity to colchicine

  16. History of an allergic reaction or significant sensitivity to aspirin (patients meeting this exclusion criterion will not be randomized to receive aspirin or placebo but can be randomized to receive colchicine or placebo)

  17. Chronic treatment with an anti-inflammatory agent (for example, anti-TNF-alpha or nonsteroidal anti-inflammatory drug (NSAID))

  18. Use of an investigational chemical agent less than 30 days or 5 half-lives prior to the screening visit (whichever is longer)

  19. Patient is considered by the investigator, for any reason, to be an unsuitable candidate for the study.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Verhütung
  • Zuteilung: Zufällig
  • Interventionsmodell: Fakultätszuweisung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Aktiver Komparator: Anti-thrombotic arm

For patients eligible for aspirin therapy arm.

40 mg non-enteric-coated tablet taken twice daily.

non-enteric-coated tablet taken twice daily.

0.5 mg tablet taken once daily

tablet taken once daily.

Placebo-Komparator: Anti-thrombotic arm (Placebo)

For patients eligible for aspirin therapy arm.

40 mg non-enteric-coated tablet taken twice daily.

non-enteric-coated tablet taken twice daily.

0.5 mg tablet taken once daily

tablet taken once daily.

Aktiver Komparator: Anti-inflammatory arm

For patients ineligible for aspirin therapy arm.

0.5 mg tablet taken once daily

tablet taken once daily.

Placebo-Komparator: Anti-inflammatory arm (Placebo)

For patients ineligible for aspirin therapy arm.

0.5 mg tablet taken once daily

tablet taken once daily.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
First event of the composite of cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction, non-fatal stroke, or urgent hospitalization for angina requiring coronary revascularization.
Zeitfenster: From randomization to occurrence of first event, assessed up to 60 months.

The number of participants having at least one of the composite of the primary endpoint.

From randomization to occurrence of first event, assessed up to 60 months.

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Cardiovascular Death
Zeitfenster: From randomization to cardiovascular death, assessed up to 60 months.

The number of participants having a cardiovascular death.

From randomization to cardiovascular death, assessed up to 60 months.
First Event of Resuscitated Cardiac Arrest
Zeitfenster: From randomization to event, assessed up to 60 months.

The number of participants having at least 1 resuscitated cardiac arrest.

From randomization to event, assessed up to 60 months.
First Event of Non-fatal Myocardial Infarction
Zeitfenster: From randomization to event, assessed up to 60 months.

The number of participants having at least 1 myocardial infarction.

From randomization to event, assessed up to 60 months.
First Event of Non-fatal Stroke
Zeitfenster: From randomization to event, assessed up to 60 months

The number of participants having at least 1 stroke.

From randomization to event, assessed up to 60 months
First Occurrence of Urgent Hospitalization for Angina Requiring Coronary Revascularization
Zeitfenster: From randomization to occurrence, assessed up to 60 months.

The number of participants having at least 1 urgent hospitalization for angina requiring coronary revascularization.

From randomization to occurrence, assessed up to 60 months.
First Event of Atrial Fibrillation
Zeitfenster: From randomization to event, assessed up to 60 months.

The number of participants having at least 1 atrial fibrillation.

From randomization to event, assessed up to 60 months.
First Occurrence of Heart Failure Hospitalization
Zeitfenster: From randomization to occurrence, assessed up to 60 months.

The number of participants having at least 1 heart failure hospitalization.

From randomization to occurrence, assessed up to 60 months.
First Occurrence of Coronary Revascularization
Zeitfenster: From randomization to occurrence, assessed up to 60 months.

The number of participants having at least 1 coronary revascularization.

From randomization to occurrence, assessed up to 60 months.
MoCA Scores Assessed Over Time
Zeitfenster: From randomization to yearly follow-ups until the end-of-study visit, assessed up to 60 months.

Change from randomization in MoCA score at yearly follow-ups (excluding the first-year visit) until the end-of-study visit.

From randomization to yearly follow-ups until the end-of-study visit, assessed up to 60 months.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

21. Dezember 2022

Primärer Abschluss (Geschätzt)

1. Dezember 2027

Studienabschluss (Geschätzt)

1. Dezember 2027

Studienanmeldedaten

Zuerst eingereicht

11. November 2022

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

30. November 2022

Zuerst gepostet (Tatsächlich)

1. Dezember 2022

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

6. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

5. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • MHICC-2021-001

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .